Join to View Full Profile
1275 York AvenueNew York, NY 10065
Dr. Oved is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Joseph Oved, MD, is a pediatric hematology and oncology specialist based in New York, NY. He graduated from the New York University School of Medicine in 2013 and completed his pediatrics residency at New York Presbyterian Hospital (Cornell Campus) in 2016. Dr. Oved is experienced in transplantation for non-malignant disorders and in particular inborn errors of immunity and bone marrow failure syndromes. A second focus of his work involves reducing toxicities from hematopoietic cell transplantation and specifically trying to develop non-chemotherapeutic agents for conditioning regimens. He has written several innovative multi-center clinical trials in these areas and his research has been featured in reputed journals such as The Lancet and Cell Stem Cell.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2013 - 2016
New York University School of MedicineClass of 2013
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2021 - 2027
NY State Medical License 2018 - 2027
PA State Medical License 2016 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia.Masanori Yoshida, Sushree S Sahoo, Paula Y Arnold, Carmelo Gurnari, Anaïs J C N van Leeuwen
Nature Genetics. 2026-05-01 - Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.Jessie L Alexander, Blachy J Dávila Saldaña, Ruta Brazauskas, Sravya Gethika Dammalapati, Linda M Griffith
Blood Advances. 2026-03-10 - 1 citationsCXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.Joseph M Rocco, Joseph H Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair
Blood. 2026-02-26
Grant Support
- Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic AnemiaSLOAN-KETTERING INST CAN RESEARCH2024–2028
- Phase 2 Bridging Pre-transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)SLOAN-KETTERING INST CAN RESEARCH2023–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
